<DOC>
	<DOC>NCT02653976</DOC>
	<brief_summary>This study is a phase 2 multinational, multicenter, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of SP-02L monotherapy in relapsed or refractory patients with peripheral T-cell lymphoma.</brief_summary>
	<brief_title>A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
	<criteria>Patients with a Japanese, Korean, Taiwanese, or Chinese ethnic background of each country/region Patients aged â‰¥20 years on the date of informed consent Patients with histologically confirmed diagnosis of one of the following: Peripheral Tcell lymphoma not otherwise specified (PTCLNOS) Angioimmunoblastic Tcell Lymphoma (AITL) Anaplastic large cell lymphoma (ALCL), (ALKpositive/negative) Relapsed or refractory patients with a treatment history of at least one regimen with antitumor agents for the above disease Have at least 1 measurable lesion Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 Patients with a life expectancy of at least 3 months as determined by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>